GSK agreed to pay up to $3.3 billion to acquire vaccine maker Affinivax and its new technology that could allow broader vaccination against common diseases
GSK PLC agreed to pay up to $3.3 billion to acquire vaccine maker Affinivax Inc., in a deal that would hand thea new vaccine technology targeting common bacterial diseases such as meningitis and pneumonia.
The British pharmaceutical company, formerly known as GlaxoSmithKline, said it would pay $2.1 billion upfront to buy the Boston-based company, with a further $1.2 billion in what it called milestone payments if Affinivax meets certain goals.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GSK Buys Vaccine Developer Affinivax in $3.3 Billion DealAffinivax's latest vaccine fights pneumonia, meningitis, and bloodstream infections.
Read more »
Chibi Clash Next-Gen Metaverse Game Secures $3 Million, Announces IDOChibi Clash shares details of its private sale backed by top VC firms and angel investors
Read more »
Ethereum Transaction Fees Hit a 10-Month Low as Gas Costs per Transfer Sink Below $3 – Altcoins Bitcoin NewsThe average Ethereum network fee has dropped to the lowest value in over ten months after fees hit a low of $2.96 per transaction on Sunday.
Read more »
GSK Buys Vaccine Developer Affinivax in $3.3 Billion DealAffinivax's latest vaccine fights pneumonia, meningitis, and bloodstream infections.
Read more »
Israel signs landmark free trade agreement with UAEThe deal eliminates bilateral tariffs on 96 percent of goods and aims to boost trade volume between the two countries to up to $10 billion.
Read more »
Long COVID risk falls only slightly after vaccination, huge study showsVaccination against SARS-CoV-2 lowers the risk of long COVID after infection by only about 15%, according to a study of more than 13 million people
Read more »